Our application, titled “Recombinant DNA Technologies for Multiplex Genetic Assays in Human Cells” was funded by the National Institutes of Health, National Institute for General Medical Sciences. This five year, $250,000 direct cost per year grant will support our continued efforts pairing landing pad -based cell engineering with multiplex assays to unlock new aspects of protein and cell biology, as well as improving our understanding of human genetics. Goals include creating generalizable, multiplex methods for functional complementation, fluorescent transcriptional reporters, & large-scale cDNA screening. Thank you NIH NIGMS for supporting us with this wonderful funding mechanism!